These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 34715820)

  • 21. Phase I/II trial of capecitabine, oxaliplatin, and irinotecan in combination with bevacizumab in first line treatment of metastatic colorectal cancer.
    Bazarbashi S; Aljubran A; Alzahrani A; Mohieldin A; Soudy H; Shoukri M
    Cancer Med; 2015 Oct; 4(10):1505-13. PubMed ID: 26207614
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial.
    Cremolini C; Antoniotti C; Rossini D; Lonardi S; Loupakis F; Pietrantonio F; Bordonaro R; Latiano TP; Tamburini E; Santini D; Passardi A; Marmorino F; Grande R; Aprile G; Zaniboni A; Murgioni S; Granetto C; Buonadonna A; Moretto R; Corallo S; Cordio S; Antonuzzo L; Tomasello G; Masi G; Ronzoni M; Di Donato S; Carlomagno C; Clavarezza M; Ritorto G; Mambrini A; Roselli M; Cupini S; Mammoliti S; Fenocchio E; Corgna E; Zagonel V; Fontanini G; Ugolini C; Boni L; Falcone A;
    Lancet Oncol; 2020 Apr; 21(4):497-507. PubMed ID: 32164906
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatments after progression to first-line FOLFOXIRI and bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies by GONO.
    Rossini D; Lonardi S; Antoniotti C; Santini D; Tomasello G; Ermacora P; Germani MM; Bergamo F; Ricci V; Caponnetto S; Moretto R; Zaniboni A; Pietrantonio F; Buonadonna A; Ritorto G; Masi G; Latiano TP; Rapisardi S; Falcone A; Cremolini C
    Br J Cancer; 2021 Jan; 124(1):183-190. PubMed ID: 33024268
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bevacizumab beyond first progression is associated with prolonged overall survival in metastatic colorectal cancer: results from a large observational cohort study (BRiTE).
    Grothey A; Sugrue MM; Purdie DM; Dong W; Sargent D; Hedrick E; Kozloff M
    J Clin Oncol; 2008 Nov; 26(33):5326-34. PubMed ID: 18854571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Morphologic response to chemotherapy containing bevacizumab in patients with colorectal liver metastases: A post hoc analysis of the WJOG4407G phase III study.
    Hosokawa A; Yamazaki K; Matsuda C; Ueda S; Kusaba H; Okamura S; Tsuda M; Tamura T; Shinozaki K; Tsushima T; Tsuda T; Shirakawa T; Yamashita H; Morita S; Hironaka S; Muro K
    Medicine (Baltimore); 2020 Sep; 99(36):e22060. PubMed ID: 32899071
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasma Angiogenic Factors as Predictors of the Efficacy of Second-line Chemotherapy Combined with Angiogenesis Inhibitors in Metastatic Colorectal Cancer: Results From the GI-SCREEN CRC-Ukit Study.
    Yuki S; Yamazaki K; Sunakawa Y; Taniguchi H; Bando H; Shiozawa M; Nishina T; Yasui H; Kanazawa A; Ando K; Horita Y; Goto M; Okano N; Moriwaki T; Satoh T; Tsuji A; Yamashita K; Asano C; Abe Y; Nomura S; Yoshino T
    Clin Colorectal Cancer; 2024 Jun; 23(2):147-159.e7. PubMed ID: 38331650
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combination therapy of bevacizumab with either S-1 and irinotecan or mFOLFOX6/CapeOX as first-line treatment of metastatic colorectal cancer (TRICOLORE): Exploratory analysis of RAS status and primary tumour location in a randomised, open-label, phase III, non-inferiority trial.
    Denda T; Takashima A; Gamoh M; Iwanaga I; Komatsu Y; Takahashi M; Nakamura M; Ohori H; Sakashita A; Tsuda M; Kobayashi Y; Baba H; Kotake M; Ishioka C; Yamada Y; Sato A; Yuki S; Morita S; Takahashi S; Yamaguchi T; Shimada K
    Eur J Cancer; 2021 Sep; 154():296-306. PubMed ID: 34304054
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Observational Cohort Study of Patients With Metastatic Colorectal Cancer Initiating Chemotherapy in Combination With Bevacizumab (CONCERT).
    Bennouna J; Phelip JM; André T; Asselain B; Sébastien Koné ; Ducreux M
    Clin Colorectal Cancer; 2017 Jun; 16(2):129-140.e4. PubMed ID: 28277294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-World Evidence on Second-Line Treatment of Metastatic Colorectal Cancer Using Fluoropyrimidine, Irinotecan, and Angiogenesis Inhibitor.
    Yamazaki K; Yuki S; Oki E; Sano F; Makishima M; Aoki K; Hamano T; Yamanaka T
    Clin Colorectal Cancer; 2021 Sep; 20(3):e173-e184. PubMed ID: 33875364
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prognostic Impact of IL6 Genetic Variants in Patients with Metastatic Colorectal Cancer Treated with Bevacizumab-Based Chemotherapy.
    Matsusaka S; Hanna DL; Cao S; Zhang W; Yang D; Ning Y; Sunakawa Y; Okazaki S; Berger MD; Miyamato Y; Parekh A; Stintzing S; Loupakis F; Lenz HJ
    Clin Cancer Res; 2016 Jul; 22(13):3218-26. PubMed ID: 26839145
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Triplet Chemotherapy (FOLFOXIRI) Plus Bevacizumab Versus Doublet Chemotherapy (FOLFOX/FOLFIRI) Plus Bevacizumab in Conversion Therapy for Metastatic Colorectal Cancer: a Meta-Analysis.
    Shui L; Wu YS; Lin H; Shui P; Sun Q; Chen X
    Cell Physiol Biochem; 2018; 48(5):1870-1881. PubMed ID: 30092572
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase II Randomized Trial of Sequential or Concurrent FOLFOXIRI-Bevacizumab Versus FOLFOX-Bevacizumab for Metastatic Colorectal Cancer (STEAM).
    Hurwitz HI; Tan BR; Reeves JA; Xiong H; Somer B; Lenz HJ; Hochster HS; Scappaticci F; Palma JF; Price R; Lee JJ; Nicholas A; Sommer N; Bendell J
    Oncologist; 2019 Jul; 24(7):921-932. PubMed ID: 30552157
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination therapy of capecitabine, irinotecan, oxaliplatin, and bevacizumab as a first-line treatment for metastatic colorectal cancer: Safety lead-in results from the QUATTRO-II study.
    Kotani D; Yoshino T; Kotaka M; Kawazoe A; Masuishi T; Taniguchi H; Yamazaki K; Yamanaka T; Oki E; Muro K; Komatsu Y; Bando H; Satake H; Kato T; Tsuji A
    Invest New Drugs; 2021 Dec; 39(6):1649-1655. PubMed ID: 34019214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized phase III study of bevacizumab plus FOLFIRI and bevacizumab plus mFOLFOX6 as first-line treatment for patients with metastatic colorectal cancer (WJOG4407G).
    Yamazaki K; Nagase M; Tamagawa H; Ueda S; Tamura T; Murata K; Eguchi Nakajima T; Baba E; Tsuda M; Moriwaki T; Esaki T; Tsuji Y; Muro K; Taira K; Denda T; Funai S; Shinozaki K; Yamashita H; Sugimoto N; Okuno T; Nishina T; Umeki M; Kurimoto T; Takayama T; Tsuji A; Yoshida M; Hosokawa A; Shibata Y; Suyama K; Okabe M; Suzuki K; Seki N; Kawakami K; Sato M; Fujikawa K; Hirashima T; Shimura T; Taku K; Otsuji T; Tamura F; Shinozaki E; Nakashima K; Hara H; Tsushima T; Ando M; Morita S; Boku N; Hyodo I
    Ann Oncol; 2016 Aug; 27(8):1539-46. PubMed ID: 27177863
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Primary Tumour Resection Could Improve the Survival of Unresectable Metastatic Colorectal Cancer Patients Receiving Bevacizumab-Containing Chemotherapy.
    Wang Z; Liang L; Yu Y; Wang Y; Zhuang R; Chen Y; Cui Y; Zhou Y; Liu T
    Cell Physiol Biochem; 2016; 39(3):1239-46. PubMed ID: 27595400
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature.
    Chan DL; Pavlakis N; Shapiro J; Price TJ; Karapetis CS; Tebbutt NC; Segelov E
    PLoS One; 2015; 10(8):e0135599. PubMed ID: 26275292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study.
    Lièvre A; Samalin E; Mitry E; Assenat E; Boyer-Gestin C; Lepère C; Bachet JB; Portales F; Vaillant JN; Ychou M; Rougier P
    BMC Cancer; 2009 Sep; 9():347. PubMed ID: 19785749
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Bevacizumab as a second- or later-line of treatment for metastatic colorectal cancer.
    Park LC; Lee HS; Shin SH; Park SJ; Park MI; Oh SY; Kwon HC; Baek JH; Choi YJ; Kang MJ; Kim YS
    World J Gastroenterol; 2012 Mar; 18(10):1104-9. PubMed ID: 22416186
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II trial of chemotherapy plus bevacizumab as second-line therapy for patients with metastatic colorectal cancer that progressed on bevacizumab with chemotherapy: the Gunma Clinical Oncology Group (GCOG) trial 001 SILK study.
    Tsutsumi S; Ishibashi K; Uchida N; Ojima H; Hosouchi Y; Yashuda N; Kigure W; Yamauchi S; Asao T; Ishida H; Kuwano H
    Oncology; 2012; 83(3):151-7. PubMed ID: 22889925
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study).
    Moriwaki T; Bando H; Takashima A; Yamazaki K; Esaki T; Yamashita K; Fukunaga M; Miyake Y; Katsumata K; Kato S; Satoh T; Ozeki M; Baba E; Yoshida S; Boku N; Hyodo I
    Med Oncol; 2012 Dec; 29(4):2842-8. PubMed ID: 22209842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.